Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04002947 · ClinicalTrials.gov registry record · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
A Phase 2 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin's Lymphoma, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
- 1
- Study location
NCT04002947: Recruiting Phase 2 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin's Lymphoma, sponsored by National Cancer Institute (NCI).
NCT04002947 is a Phase 2 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin's Lymphoma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 132 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04002947, a Phase 2 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin's Lymphoma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate. Objective: To see if the drug acalabrutinib given with rituximab and standard combination chemotherapy can improve the cure rate of aggressive B-cell lymphomas such as diffuse large B-cell lymphoma. Eligibility: People ages 18 and older with an aggressive B-cell lymphomas that have not been treated Design: Participants will be screened with: Blood and urine tests Physical exam Medical history Tumor biopsy Bone marrow biopsy: A needle will remove marrow from the participant s hipbone. Lumbar puncture: If necessary, a needle will remove fluid from the participant s spinal canal. Imaging scans Participants will take the study drug for up to 14 days. It is a pill taken 2 times a day. Then they will have more scans. They will get rituximab and chemotherapy. They may get these drugs through a needle in an arm vein. Or they may them through a tube placed in a vein in their chest or in their neck. They might also keep taking the study drug. Each treatment cycle lasts 21 days. They will have up to 6 cycles. Participants may have 4 doses of another drug injected into their spinal fluid. Participants will have repeats of the screening tests throughout the study. Participants will have a follow-up visit 30 days after their last treatment, then every 3 months for 2 years, then every 6 months for 3 years, and then yearly.
Primary Outcome
Number of patients who achieve a CR, PR or SD
Conditions Studied
Interventions
- BIOLOGICAL Rituximab
- DRUG Acalabrutinib
- DRUG DA-EPOCH
- DRUG CHOP
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 2 |
What NCT04002947 shows while recruiting
NCT04002947 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (39% lower).
The record links to 4 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Rituximab is the first listed.
NCT04002947 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04002947 about?
NCT04002947 is a clinical study titled "Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma". Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate. Objective: To se...
What is the current status of trial NCT04002947?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2019-08-05. Estimated completion is 2030-03-31.
What conditions does trial NCT04002947 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Non-Hodgkin's Lymphoma, DLBCL, NHL.
What interventions are being tested in trial NCT04002947?
The interventions under investigation include: Rituximab (BIOLOGICAL), Acalabrutinib (DRUG), DA-EPOCH (DRUG), CHOP (DRUG).
Who is sponsoring clinical trial NCT04002947?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04002947 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04002947's enrollment target sits among peer trials
132 38th of 114 higher than 77 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
RECRUITING · Phase 2
-
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
- NCT04623099 · 132 participants · Phase 4
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI